Developments in laboratory diagnostics for isocyanate asthma

Current Opinion in Allergy and Clinical Immunology

Volumn 7, Issue 2, 2007, Pages 138-145

  Wisnewski, Adam V ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; Asthma; Diagnosis; Exposure; Isocyanate

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; ISOCYANATE; ISOCYANIC ACID DERIVATIVE;

CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; ENVIRONMENTAL EXPOSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; GOLD STANDARD; HUMAN; IMMUNOASSAY; IMMUNOPATHOGENESIS; INHALATION TEST; LABORATORY DIAGNOSIS; LABORATORY TEST; MEDLINE; OCCUPATIONAL ASTHMA; PRIORITY JOURNAL; PUBLICATION; RADIOALLERGOSORBENT TEST; REVIEW; SKIN SENSITIZATION; WORK ENVIRONMENT; WORKPLACE;

ASTHMA; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOLOGIC TESTS; ISOCYANATES; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE;

EID: 33947164641     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3280895d22     Document Type: Review

References (62)

1. Bonauto DK, Sumner AD, Curwick CC, et al. Work-related asthma in the spray-on truck bed lining industry. J Occup Environ Med 2005; 47:514-517.
2. Taramian A, Doosthoseini K, Mirshokraii SA, Faezipour M. Particleboard manufacturing: an innovative way to recycle paper sludge. Waste Manag 2007; In press.
3. Berode M, Jost M, Ruegger M, Savolainen H. Host factors in occupational diisocyanate asthma: a Swiss longitudinal study. Int Arch Occup Environ Health 2005; 78:158-163.
4. Robert A, Ducos P, Francin JM, Marsan P. Biological monitoring of workers exposed to 4,4′-methylenediphenyl diisocyanate (MDI) in 19 French polyurethane industries. Int Arch Occup Environ Health 2007; In press.
5. Sennbro CJ, Littorin M, Tinnerberg H, Jonsson BA. Upper reference limits for biomarkers of exposure to aromatic diisocyanates. Int Arch Occup Environ Health 2005; 78:541-546.
6. Sennbro CJ, Lindh CH, Mattsson C, et al. Biological monitoring of exposure to 1,5-naphthalene diisocyanate and 4,4′-methylenediphenyl diisocyanate. Int Arch Occup Environ Health 2006; 79:647-653. Biomarkers of isocyanate exposure are detectable by gas chromatography mass spectrometry methods after derivitization of hyrolyzed urine and plasma, documenting internal exposure on the job. There was a wide range of individual variability, which questions the utility of the biomarker as a surrogate for exposure when assessing a large population of workers.
7. Boutin M, Dufresne A, Ostiguy C, Lesage J. Determination of airborne isocyanates generated during the thermal degradation of car paint in body repair shops. Ann Occup Hyg 2006; 50:385-393. A poorly recognized exposure risk occurs when isocyanates are released by thermal degredation that occurs with cutting, grinding and orbital sanding operations in autobody shops.
8. Tarlo SM, Liss GM. Prevention of occupational asthma - practical implications for occupational physicians. Occup Med (Lond) 2005; 55:588-594.
9. Pisati G, Baruffini A, Bernabeo F, et al. Rechallenging subjects with occupational asthma due to toluene diisocyanate (TDI), after long-term removal from exposure. Int Arch Occup Environ Health 2007; In press.
10. Jones MG, Floyd A, Nouri-Aria KT, et al. Is occupational asthma to diisocyanates a non-IgE-mediated disease? J Allergy Clin Immunol 2006; 117:663-669. The data extend the lack of isocyanate-induced IgE to the airway submucosa via bronchoscopy and in-situ hybridization. The subjects were recruited from a specialist clinic after referal by their general practitioner or occupational health physician. Before the study, the majority of subjects had previously been away from exposure for more than 30 days, which may have effected their results.
11. Rudbeck MG, Omland O. Work-related asthma caused by IgE-verified allergy to methylene di-isocynate. Ugeskr Laeger 2006; 168:1345-1346. A case report from a foreign journal documenting MDI asthma with MDI-specific IgE.
12. Kim SH, Oh HB, Lee KW, et al. HLA DRB1*15-DPB1*05 haplotype: a susceptible gene marker for isocyanate-induced occupational asthma? Allergy 2006; 61:891-894. The association of human leukocyte antigen haplotypes with isocyanate asthma support the role of the dendritic/T cell responses in isocyanate asthma. The effect is weak, however, individual human leukocyte antigen alleles were not significantly associated, and differed from those previously associated with isocyanate asthma in earlier studies by other authors.
13. Tarkowski M, Vanoirbeek JA, Vanhooren HM, et al. Immunological determinants of ventilatory changes induced in mice by dermal sensitization and respiratory challenge with toluene diisocyanate. Am J Physiol Lung Cell Mol Physiol 2007; 292:L207-L214. An extension of previous work by the same authors, further exploring the mechanisms of dermal exposure leading to systemic sensitization and asthma upon subsequent airway exposure. The study highlights the potential for skin to serve as an effective route of sensitization and exposure-induced pathology that involves a mixture of T helper type 1 and 2 responses.
14. Ban M, Morel G, Langonne I, et al. TDI can induce respiratory allergy with Th2-dominated response in mice. Toxicology 2006; 218:39-47. This study highlights the possible contribution of skin exposure to asthma development, and suggests that the skin may be the most effective exposure route for inducing allergic (T helper type 2) responses to isocyanate.
15. Furusho S, Myou S, Fujimura M, et al. Role of intercellular adhesion molecule-1 in a murine model of toluene diisocyanate-induced asthma. Clin Exp Allergy 2006; 36:1294-1302.
16. Lee KS, Park SJ, Kim SR, et al. Modulation of airway remodeling and airway inflammation by peroxisome proliferator-activated receptor gamma in a murine model of toluene diisocyanate-induced asthma. J Immunol 2006; 177:5248-5257. The peroxisome proliferator-activated receptor gamma agonist, rosiglitazone, or pioglitazone reduce pathology in a mouse model of TDI asthma. Could these drugs help ameliorate isocyanate asthma in humans?
17. Matheson JM, Johnson VJ, Luster MI. Immune mediators in a murine model for occupational asthma: studies with toluene diisocyanate. Toxicol Sci 2005; 84:99-109.
18. Matheson JM, Johnson VJ, Vallyathan V, Luster MI. Exposure and immunological determinants in a murine model for toluene diisocyanate (TDI) asthma. Toxicol Sci 2005; 84:88-98.
19. Karol MH, Kramarik JA, Ferguson J. Methods to assess RAST results in patients exposed to chemical allergens. Allergy 1995; 50:48-54.
20. Bernstein DI, Cartier A, Côté J, et al. Diisocyanate antigen-stimulated monocyte chemoattractant protein-1 synthesis has greater test efficiency than specific antibodies for identification of diisocyanate asthma. Am J Respir Crit Care Med 2002; 166:445-450.
21. Cartier A, Grammer L, Malo JL, et al. Specific serum antibodies against isocyanates: association with occupational asthma. J Allergy Clin Immunol 1989; 84:507-514.
22. Ye YM, Kim CW, Kim HR, et al. Biophysical determinants of toluene diisocyanate antigenicity associated with exposure and asthma. J Allergy Clin Immunol 2006; 118:885-891. Promising improvements of TDI-RAST for the diagnosis of TDI asthma achieved through a multidisciplinary approach. Matrix-assisted laser desorption ionization mass spectrometry defines differences between vapor versus liquid TDI-albumin conjugates, which correlate with antigenicity. Vapor TDI-albumin-specific IgE was found in 29 out of 66 TDI asthmatic sufferers (44%), but only seven out of 167 of exposed control (4%) and none out of 64 atopic (non-isocyanate) asthmatic individuals.
23. Wisnewski AV, Liu Q, Liu J, Redlich CA. Glutathione protects human airway proteins and epithelial cells from isocyanates. Clin Exp Allergy 2005; 35:352-357.
24. Lee CT, Ylostalo J, Friedman M, Hoyle GW. Gene expression profiling in mouse lung following polymeric hexamethylene diisocyanate exposure. Toxicol Appl Pharmacol 2005; 205:53-64.
25. Izuhara K, Saito H. Microarray-based identification of novel biomarkers in asthma. Allergol Int 2006; 55:361-367. An excellent review of applying gene chip technology to identify asthma biomarkers.
26. Infuhr D, Crameri R, Lamers R, Achatz G. Molecular and cellular targets of anti-IgE antibodies. Allergy 2005; 60:977-985.
27. Tee RD, Cullinan P, Welch J, et al. Specific IgE to isocyanates: a useful diagnostic role in occupational asthma. J Allergy Clin Immunol 1998; 101:709-715.
28. Hellman L, Regulation of IgE homeostasis, and the identification of potential targets for therapeutic intervention. Biomed Pharmacother 2007; In press.
29. Patterson R, Oh SH, Roberts M, Hsu CC. Massive polyclonal hyperimmunoglobulinemia E, eosinophilia and increased IgE-bearing lymphocytes. Am J Med 1975; 58:553-558.
30. Pronk A, Yu F, Vlaanderen J, et al. Dermal, inhalation, and internal exposure to 1,6-HDI and its oligomers in car body repair shop workers and industrial spray painters. Occup Environ Med 2006; 63:624-631. Liquid chromatography-mass spectrometry/mass spectrometry analysis of hydrolyzed, derivatized urine prove that internal isocyanate exposure occurs in painting industry, in bystanders as well as spray painters themselves. The analytical equipment required for analysis is substantial, which may limit the practical application of exposure monitoring.
31. Redlich CA, Stowe MH, Coren BA, et al. Diisocyanate-exposed auto body shop workers: a one-year follow-up. Am J Ind Med 2002; 42:511-518.
32. Sakai T, Morita Y, Roh J, et al. Improvement in the GC-MS method for determining urinary toluene-diamine and its application to the biological monitoring of workers exposed to toluene-diisocyanate. Int Arch Occup Environ Health 2005; 78:459-466.
33. Gagne S, Lesage J, Ostiguy C, et al. Quantitative determination of hexamethylene diisocyanate (HDI), 2,4-toluene diisocyanate (2,4-TDI) and 2,6-toluene diisocyanate (2,6-TDI) monomers at ppt levels in air by alkaline adduct coordination ionspray tandem mass spectrometry. J Environ Monit 2005; 7:145-150.
34. Ogawa M, Oyama T, Isse T, et al. Hemoglobin adducts as a marker of exposure to chemical substances, especially PRTR class I designated chemical substances. J Occup Health 2006; 48:314-328.
35. 3). Additional high-exposure activities, mixing/casting polyurethane products, semi-automatic moulding, and resin applications have been suggested to involve skin exposure.
36. Hogberg J, Larsson K, Albin M, et al. Comments on 'Respiratory effects of toluene diisocyanate in the workplace: a discussion of exposure-response relationships'. Crit Rev Toxicol 2005; 35:459-460; author reply 461-462.
37. Isocyanate exposure in an autobody repair and collision center. J Occup Environ Hyg 2006; 3: D24-D27.
38. Church JA, Leibl H, Stein MR, et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol 2006; 26:388-395. Typical serum IgG half-life approximately 35 days.
39. Wisnewski AV, Stowe MH, Cartier A, et al. Isocyanate vapor-induced antigenicity of human albumin. J Allergy Clin Immunol 2004; 113:1178-1184.
40. Aul DJ, Bhaumik A, Kennedy AL, et al. Specific IgG response to monomeric and polymeric diphenylmethane diisocyanate conjugates in subjects with respiratory reactions to isocyanates. J Allergy Clin Immunol 1999; 103:749-755.
41. Bernstein DI, Ott MG, Woolhiser M, et al. Evaluation of antibody binding to diisocyanate protein conjugates in a general population. Ann Allergy Asthma Immunol 2006; 97:357-364. The data suggest that isocyanate-specific IgGmay be a biomarker of exposure, and is not found in the general population when the testing (enzyme-linked immunosorbent assay) is based on isocyanate-albumin conjugates with low substitution ratios (3:1). IgG enzyme-linked immunosorbent assay test results with serum dilutions less than 1:10, or isocyanate-albumin conjugates with high substitution ratios (>19:1), should be interpreted cautiously. Non-occupational sources of exposure (e.g. hobbies, home improvement) should also be considered.
42. Frick-Engfeldt M, Zimerson E, Karlsson D, et al. Chemical analysis of 2,4-toluene diisocyanate,16-hexamethylene diisocyanate and isophorone diisocyanate in petrolatum patch-test preparations. Dermatitis 2005; 16:130-135.
43. Hannu T, Estlander T, Jolanki R. Allergic contact dermatitis due to MDI and MDA from accidental occupational exposure. Contact Dermatitis 2005; 52:108-109.
44. Pauluhn J. Brown Norway rat asthma model of diphenylmethane 4,4′-diisocyanate. Inhal Toxicol 2005; 17:729-739.
45. Pauluhn J, Woolhiser MR, Bloemen L. Repeated inhalation challenge with diphenylmethane-4,4′-diisocyanate in brown Norway rats leads to a time-related increase of neutrophils in bronchoalveolar lavage after topical induction. Inhal Toxicol 2005; 17:67-78.
46. Bello D, Smith TJ, Woskie SR, et al. An FTIR investigation of isocyanate skin absorption using in vitro guinea pig skin. J Environ Monit 2006; 8:523-529. Novel application of Fourier transform infrared spectrometry to isocyanate research that warrants further exploration of detection limits and practicality.
47. Selgrade M, Boykin EH, Haykal-Coates N, et al. Inconsistencies between cytokine profiles, antibody responses, and respiratory hyperresponsiveness following dermal exposure to isocyanates. Toxicol Sci 2006; 94:108-117. Skin exposure to isocyanates increases serum IgE and cytokine production, highlighting the potential role of the skin in the development of asthma.
48. Nabe T, Yamauchi K, Shinjo Y, et al. Delayed-type asthmatic response induced by repeated intratracheal exposure to toluene-2,4-diisocyanate in guinea pigs. Int Arch Allergy Immunol 2005; 137:115-124.
49. Petsonk EL, Wang ML, Lewis DM, et al. Asthma-like symptoms in wood product plant workers exposed to methylene diphenyl diisocyanate. Chest 2000; 118:1183-1193.
50. Fent KW, Jayaraj K, Gold A, et al. Tape-strip sampling for measuring dermal exposure to 1,6-hexamethylene diisocyanate. Scand J Work Environ Health 2006; 32:225-240. A novel non-invasive method for detecting isocyanate on the human skin surface represents a potentially important approach to future studies on the role of skin in developing isocyanate sensitization.
51. Flynn MR, Koto Y, Fent K, Nylander-French LA. Modeling dermal exposure - an illustration for spray painting applications. J Occup Environ Hyg 2006; 3:475-480. A mathmatical model of skin exposure calls attention to the potential role of hair in the skin microenvironment to increase isocyanate deposition. Similar modeling of disrupted or wounded skin would be of interest.
52. Chen SE, Bernstein IL. The guinea pig model of diisocyanate sensitization. I. Immunologic studies. J Allergy Clin Immunol 1982; 70:383-392.
53. Jin RZ, Karol MH. Intra- and intermolecular reactions of 4,4′-diisocyanatodiphenylmethane with human serum albumin. Chem Res Toxicol 1988; 1:281-287.
54. Baur X. Immunologic cross-reactivity between different albumin-bound isocyanates. J Allergy Clin Immunol 1983; 71:197-205.
55. Wass U, Belin L. Immunologic specificity of isocyanate-induced IgE antibodies in serum from 10 sensitized workers. J Allergy Clin Immunol 1989; 83:126-135.
56. Cummings BJ, Booth KS. Industrial hygiene sampling for airborne TDI in six flexible slabstock foam manufacturing facilities in the United States: a comparison of the short-term and long-term sampling data. Appl Occup Environ Hyg 2002; 17:863-871.
57. Baur X, Chen Z, Flagge A, et al. EAST and CAP specificity for the evaluation of IgE and IgG antibodies to diisocyanate-HSA conjugates. Int Arch Allergy Immunol 1996; 110:332-338.
58. Bousquet J, Chanez P, Chanal I, Michel FB. Comparison between RAST and Pharmacia CAP system: a new automated specific IgE assay. J Allergy Clin Immunol 1990; 85:1039-1043.
59. Sander I, Kespohl S, Merget R, et al. A new method to bind allergens for the measurement of specific IgE antibodies. Int Arch Allergy Immunol 2005; 136:39-44.
60. Mothes N, Valenta R, Spitzauer S. Allergy testing: the role of recombinant allergens. Clin Chem Lab Med 2006; 44:125-132. A review of allergen microarrays.
61. Ogawa H, Inoue S, Ogushi F, et al. Toluene diisocyanate (TDI) induces production of inflammatory cytokines and chemokines by bronchial epithelial cells via the epidermal growth factor receptor and p38 mitogen-activated protein kinase pathways. Exp Lung Res 2006; 32:245-262. The data further indicate active involvement of the epithelium in asthma pathogenesis by suggesting that airway epithelial cells respond to isocyanate conjugated albumin conjugates (antigens) with increased activity of signalling pathways that trigger inflammatory gene expression.
62. Kuna P, Reddigari SR, Rucinski D, et al. Monocyte chemotactic and activating factor is a potent histamine-releasing factor for human basophils. J Exp Med 1992; 175:489-493.